Willgoos was previously counsel at Paul Hastings.
Willgoos leads trial and appellate teams in Hatch-Waxman and biologic drug litigations concerning blockbuster drugs. She is experienced in cases involving pharmacokinetics and pharmacodynamics, molecular and cellular biology, and drug development, including humanized antibody technology, recombinant DNA vectors, and antidepressant and dermatologic drugs.
